Adverse effects: extrapyramidal adverse effectsParkinsonism (rigidity) short term (< 3 months) Clinical diagnoses · patients with schizophrenia
ORAL FLUPHENAZINE probably leads to higher adverse effects: Extrapyramidal effects (rigidity) ‐ short… compared with PLACEBO (moderate certainty).
1 finding from 1 review
Adverse effects: Specific ‐ hypertonia/rigidity (only reported if occurred in ≥9%) during 24 hours · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ hypertonia/rigidity (only reported if… compared with COMBINATIONS: b. HALOPERIDOL + LORAZEPAM (very low certainty).
1 finding from 1 review
Adverse effects: Specific ‐ rigidity between 0‐3 days (IM phase) · patients to psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ rigidity between 0‐3 days (IM phase) compared with OTHER ANTIPSYCHOTIC: d. LOXAPINE (very low certainty).
1 finding from 1 review
Adverse effects: Specific ‐ hypertonia/rigidity (only reported if occurred in ≥9%) during 24 hours · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: specific ‐ hypertonia/rigidity (only reported if… compared with BENZODIAZEPINE: b. LORAZEPAM (very low certainty).
1 finding from 1 review
Adverse effects: extrapyramidal adverse effectsParkinsonism (rigidity) short term (< 3 months) Clinical diagnoses · patients with schizophrenia or related psychoses
PIMOZIDE showed no clear difference in adverse effects: extrapyramidal adverse effectsParkinsonism… compared with ANY ANTIPSYCHOTIC (low certainty).
1 finding from 1 review
Adverse effects: extrapyramidal adverse effects Parkinsonism (rigidity) medium term (3‐12 months) Clinical diagnoses · patients with schizophrenia or related psychoses
1 finding from 1 review
Adverse effects: extrapyramidal adverse effects Parkinsonism (rigidity) short term (< 3 months) Extrapyramidal Symptom Rating Scale (ESRS) · patients with schizophrenia or related psychoses
1 finding from 1 review
Adverse effects: extrapyramidal adverse effects Parkinsonism (rigidity) short term (< 3 months) Extrapyramidal Symptom Rating Scale (ESRS) · patients with schizophrenia or related psychoses
It is very uncertain whether PIMOZIDE changes adverse effects: extrapyramidal adverse effects: Parkinsonism… compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects: extrapyramidal adverse effects Parkinsonism (rigidity) medium term (3‐12 months) Clinical diagnoses · patients with schizophrenia or related psychoses
It is very uncertain whether PIMOZIDE changes adverse effects: extrapyramidal adverse effects:Parkinsonism… compared with PLACEBO (very low certainty).
1 finding from 1 review